U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
